Followers | 129 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Friday, March 17, 2017 1:23:56 PM
AQS1301 Topline Results within 10 days = Push to $0.40+
and there are many big news on the way to push this dirt cheap and unknown goldmine higher .This will be the next 10+ bagger after Theratechnologies (TH.T) and BioSyent (RX.V) . AQS is maybe the cheapest Bio gem you can get in the US.
Market-Cap: $15 Million
Cash: $4 Million << enough untill mid 2018
Price: $0.20
AQS1301 topline results in 1Q 2017
Operational profitability estimated in 2017
File for CDN approval of Topiramate XR in 1H 2017
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product acquisitions in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM